

Deal Corner

January 20, 2017

MSD DIVESTS 6 BRANDS TO ZYDUS HEALTHCARE LIMITED

DEAL BRIEF

United States pharmaceutical giant Merck & Co., Inc. (known as Merck Sharp & Dohme (MSD) outside the United States and Canada), through its subsidiaries, divested its 6 brands to Zydus Cadila's wholly owned subsidiary Zydus Healthcare Limited. Pharmaceutical products in the segment of men's and women's health, wound management and cardiovascular therapy were sold under these brands.

In addition to the sale of brand names, Organon India Private Limited, an Indian subsidiary company of Merck & Co., Inc. /MSD, assigned manufacturing know-how, distribution and commercialization rights for 3 of the brands sold as part of the deal.

Press coverage relating to this transaction available at [Business Standard](#), [Economic Times](#), [Live Mint](#) and [Pharma Biz](#).

OUR ROLE

We, at [Nishith Desai Associates](#), acted as the Indian legal and regulatory counsel to MSD.

DISCLAIMER

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

Proud Moments

Legal500 Asia-Pacific: Tier 1 for Tax, Investment Funds, Labour & Employment and TMT
2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012

Chambers and Partners Asia Pacific: Band 1 for Employment, Lifesciences, Tax and TMT
2020, 2019, 2018, 2017, 2016, 2015

IFLR1000: Tier 1 for Private Equity and Project Development: Telecommunications Networks.
2020, 2019, 2018, 2017, 2014

AsiaLaw Asia-Pacific Guide 2020: Tier 1 (Outstanding) for TMT, Labour & Employment, Private Equity, Regulatory and Tax

FT Innovative Lawyers Asia Pacific 2019 Awards: NDA ranked 2nd in the Most Innovative Law Firm category (Asia-Pacific Headquartered)

RSG-Financial Times: India's Most Innovative Law Firm
2019, 2017, 2016, 2015, 2014

Benchmark Litigation Asia-Pacific: Tier 1 for Government & Regulatory and Tax
2019, 2018

Research Papers

3D Printing: Ctrl + P the Future
April 02, 2020

Dispute Resolution in India: An Introduction
April 02, 2020

Impact of Covid-19 on Contracts
March 31, 2020

Research Articles

Chambers Global Practice Guide: Gaming Laws
December 19, 2019

The Tips and Traps to Avoid When Investing in India
December 31, 2018

Evolving HR Law: Giving GCs Sleepless Nights?

Audio

Seminar: Possible Last Window for the Start-Up Community's Say on Proposed Privacy Law

February 19, 2020

Webinar: India Budget 2020: Implications for the International Community

February 05, 2020

Webinar: A New Dawn for Privacy in India: the Personal Data Protection Bill, 2019

December 17, 2019

NDA Connect

Connect with us at events, conferences and seminars.

NDA Hotline

[Click here to view Hotline archives.](#)

Video

NDA cCep - Program Video

CNBC TV18 Startup Street

Webinar: Re-thinking Indian Private Equity Exits